Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-03-23 07:30 |
PR NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT MARCH 15
|
English | 68.0 KB | ||
| 2015-03-23 07:30 |
CP nb d'actions et de droits de votes IPH
|
French | 69.3 KB | ||
| 2015-03-09 07:30 |
CP NCIC
|
French | 105.7 KB | ||
| 2015-03-09 07:30 |
PR NCIC
|
English | 98.4 KB | ||
| 2015-02-19 07:31 |
Annual report 2014 IPH
|
English | 191.3 KB | ||
| 2015-02-19 07:30 |
rapport annuel 2014 IPH
|
French | 192.4 KB | ||
| 2015-01-08 17:45 |
CP Nombre d'actions
|
French | 68.9 KB | ||
| 2015-01-08 17:45 |
CP Bilan annuel du contrat de liquidité
|
French | 69.5 KB | ||
| 2015-01-08 17:45 |
CP Full-year report on liquidity contract
|
English | 68.2 KB | ||
| 2015-01-08 17:45 |
PR Number of shares
|
English | 67.4 KB | ||
| 2014-12-19 07:31 |
Ouverture du premier essai de Phase II avec IPH2201
|
French | 88.2 KB | ||
| 2014-12-19 07:31 |
First Phase II trial with IPH2201 open in head and neck cancer
|
English | 81.7 KB | ||
| 2014-12-12 17:45 |
IPH_Essai de Phase I ipilimumab lirilumab
|
French | 76.2 KB | ||
| 2014-12-12 17:45 |
141212 ipilimumab lirilumab Phase I
|
English | 37.6 KB | ||
| 2014-12-09 07:30 |
PR ASH14
|
English | 92.7 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
